- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Tatva Chintan Pharma Chem's board approved the financial results for the quarter ended 30 June 2025. Consolidated revenue from operations was ₹116.86 Cr, with a profit of ₹6.65 Cr. Standalone revenue stood at ₹107.65 Cr, with profit at ₹5.13 Cr. Based on input from the Nomination and Remuneration Committee, the board also approved the re-appointment of Managing Director Mr. Chintan Nitinkumar Shah, two Whole-time Directors, and three Independent Directors for new terms, pending shareholder approval. The company further announced the resignation of its Chief Financial Officer, Mr. Ashok Bothra.